pulmonary arterial hypertension

June 9, 2016June 9, 2016

Crucial Molecule May Lead to Novel Therapies for Pulmonary Arterial Hypertension

In a recent study published in the The Journal of Clinical Investigation, researchers reported to have identified a crucial factor for the development of pulmonary arterial hypertension (PAH). The discovery identified a ... Read more

May 17, 2016May 25, 2016

Actelion’s Uptravi for PAH Granted Marketing Authorization by European Commission

News, Pulmonary Hypertension

The European Commission recently granted marketing authorization in the EU for Switzerland-based Actelion’s product Uptravi (selexipag) for the treatment of pulmonary arterial hypertension. PAH is a life-threatening disease characterized by abnormal constriction of the pulmonary ... Read more

May 9, 2016May 9, 2016

Insmed Incorporated to Present Data on Liposomal Technology To Treat PAH, IPF at 2016 American Thoracic Society Meeting

Asthma, News, Pulmonary Hypertension

Insmed Incorporated recently announced that it will present three ARIKAYCE™-related abstracts and one treprostinil prodrug abstract at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, May 13-18. ARIKAYCE™ ... Read more

May 5, 2016May 5, 2016

AVEO Oncology Files Provisional Patent Applications for AV-353 for PAH Treatment

News, Pulmonary Hypertension

AVEO Oncology recently filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, its Notch 3 inhibitory antibody. These are the ... Read more

April 18, 2016April 19, 2016

Karos Pharmaceuticals Advances PAH Drug Candidate into the Clinic

News, Pulmonary Hypertension

Karos Pharmaceuticals recently announced it has advanced its small molecule investigational drug candidate, KAR5585, into the clinic for the treatment of pulmonary arterial hypertension (PAH) and other rare conditions marked ... Read more

April 1, 2016April 4, 2016

EMA Grants Orphan Medicinal Status to Eiger’s PAH Treatment Ubenimex

News, Pulmonary Hypertension

The European Medicines Agency (EMA) has granted Orphan Medicinal Product status to Eiger BioPharmaceuticals‘ Bestatin (ubenimex) for the treatment of pulmonary arterial hypertension (PAH). “We are very pleased with the EMA ... Read more

March 24, 2016March 24, 2016

Actelion’s PAH Therapy, Uptravi (selexipag), Approved for Use in Australia and New Zealand

News, Pulmonary Hypertension

Actelion, Ltd., recently announced the approval of Uptravi (selexipag) by the Therapeutic Goods Administration (TGA) of Australia and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) for the treatment ... Read more

February 16, 2016February 18, 2016

PAH Treatment Long-Term Trial Results of Bellerophon’s INOpulse Are Encouraging

News, Pulmonary Hypertension

Bellerophon Therapeutics recently announced the results from the final analysis (Part 2) of its Phase 2 long-term extension clinical trial on iNO/INOpulse drug-device combination product for the treatment of patients with ... Read more

February 15, 2016February 18, 2016

In Certain People with PAH, Researchers Identify Markers for Lower Mortality Rates

News, Pulmonary Hypertension, Scleroderma

A new study demonstrated that specific antibodies could be markers for decreased mortality in people with connective tissue disease and systemic sclerosis associated with pulmonary arterial hypertension (PAH). The report in ... Read more

February 11, 2016February 18, 2016

Sildenafil May Be Better Therapy for PAH When Combined with Ambrisentan Instead of Bosentan, Study Says

News, Pulmonary Hypertension

A new study reported that sildenafil may be better suited for patients with pulmonary arterial hypertension (PAH) when given in combination with ambrisentan instead of bosentan. The study, “Pharmacokinetic and ... Read more